Infant Bacterial Valuation
| IBT-B Stock | SEK 39.40 0.60 1.55% |
At this time, the firm appears to be overvalued. Infant Bacterial retains a regular Real Value of kr31.94 per share. The prevalent price of the firm is kr39.4. Our model calculates the value of Infant Bacterial from evaluating the firm fundamentals such as Return On Equity of -0.18, shares owned by insiders of 7.23 %, and Return On Asset of -0.11 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Infant Bacterial's price fluctuation is not too volatile at this time. Calculation of the real value of Infant Bacterial is based on 3 months time horizon. Increasing Infant Bacterial's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Infant stock is determined by what a typical buyer is willing to pay for full or partial control of Infant Bacterial Therapeutics. Since Infant Bacterial is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Infant Stock. However, Infant Bacterial's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 39.4 | Real 31.94 | Hype 39.4 | Naive 42.28 |
The intrinsic value of Infant Bacterial's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Infant Bacterial's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Infant Bacterial Therapeutics helps investors to forecast how Infant stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Infant Bacterial more accurately as focusing exclusively on Infant Bacterial's fundamentals will not take into account other important factors: Infant Bacterial Total Value Analysis
Infant Bacterial Therapeutics is currently projected to have takeover price of 271.56 M with market capitalization of 560.25 M, debt of 0, and cash on hands of 386.75 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Infant Bacterial fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
271.56 M | 560.25 M | 0 | 386.75 M |
Infant Bacterial Asset Utilization
One of the ways to look at asset utilization of Infant is to check how much profit was generated for every dollar of assets it reports. Infant Bacterial retains a negative application of resources of -0.11 (percent), losing kr0.001085 for each kronor of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each kronor of resources it retains. Simply put, asset utilization of Infant Bacterial Therapeutics shows how discouraging it operates for each kronor spent on its resources.Infant Bacterial Ownership Allocation
The market capitalization of Infant Bacterial is kr560.25 Million. 30% of Infant Bacterial outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Infant Bacterial Profitability Analysis
Net Loss for the year was (44.99 M) with profit before overhead, payroll, taxes, and interest of 12 K.About Infant Bacterial Valuation
The stock valuation mechanism determines Infant Bacterial's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Infant Bacterial based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Infant Bacterial. We calculate exposure to Infant Bacterial's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Infant Bacterial's related companies.Infant Bacterial Therapeutics AB , a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company was founded in 2013 and is based in Stockholm, Sweden. Infant Bacterial is traded on Stockholm Stock Exchange in Sweden.
8 Steps to conduct Infant Bacterial's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Infant Bacterial's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Infant Bacterial's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Infant Bacterial's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Infant Bacterial's revenue streams: Identify Infant Bacterial's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Infant Bacterial's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Infant Bacterial's growth potential: Evaluate Infant Bacterial's management, business model, and growth potential.
- Determine Infant Bacterial's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Infant Bacterial's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Infant Stock Analysis
When running Infant Bacterial's price analysis, check to measure Infant Bacterial's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infant Bacterial is operating at the current time. Most of Infant Bacterial's value examination focuses on studying past and present price action to predict the probability of Infant Bacterial's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Infant Bacterial's price. Additionally, you may evaluate how the addition of Infant Bacterial to your portfolios can decrease your overall portfolio volatility.